Alexandra Gerlach, Content Producer

Pharmacists play a crucial role in supporting patients with HR+/HER2– breast cancer.

Accurate, effective screening is crucial for connecting patients with needed financial resources and support.

Patients can face barriers to BCMA-targeted treatments.

Pharmacists can be essential sources of education for patients, offering them guidance on safe use and proper dosage.

Palliative care is crucial for safe and effective medication management to relieve symptoms and improve quality of life.

Pharmacists are key resource points to navigate the nuances of keto diets and chronic health management.

The bispecific CAR T-cell therapy for treatment of multiple sclerosis is the first to target both CD19 and CD20.

Joseph Saseen offers valuable insights into the implications of the added performance and quality measures for patients and health care providers.

Propofol has a history of chronic shortage due to supply chain constraints.

The highly potent, selective URAT1 inhibitor may help reduce serum uric acid levels and treat clinically visible tophi.

The OTC antibody test can detect current or past infection but should be followed by additional testing to confirm diagnosis.

Craig Beavers discusses significance of the 2024 update to the 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure.

CAR T-cell therapy in multiple myeloma faces challenges from the immunosuppressive cells in the tumor microenvironment.

The updates are based on nationwide reports of extreme pain during IUD insertion.

Durvalumab is a human monoclonal antibody that targets and binds to PD-L1 to interrupt tumor immune-evasion tactics.

The decision is based positive data from the Deltacel-01 clinical trial.

The decision is based on clinical findings demonstrating seladelpar’s ability to effectively regulate of alkaline phosphatase values in patients.

Predicting disease progression is essential to improve the health outcomes of patients with multiple sclerosis.

Risk of developing anxiety or depression is highest within the first year after cardiovascular hospitalization.

Non-steroidal mineralocorticoid receptor antagonist, finerenone, demonstrated improved efficacy compared with existing steroidal treatment for patients.

Statins and non-statin cholesterol-lowering agents show potential in reducing the risk of liver cancer.

The findings may lead to the development of diagnostic and therapeutic targets to prevent worsening disease in patients.

Isatuximab (Sarclisa; Sanofi) in combination with standard-of-care significantly improved progression-free survival in patients with newly diagnosed multiple myeloma.

Cholesterol-lowering agents, like statins, reduced the risk of major adverse cardiovascular events and cardiovascular disease in patients with HIV.

Acalabrutinib plus venetoclax, with or without obinutuzumab, demonstrated significant improvements in progression-free survival.

CD38 density may indicate the efficacy of monoclonal antibody treatment in patients with multiple myeloma.

The findings highlight the potential for developing more efficacious combination treatments for patients with glioblastoma.

The findings show that inhibiting connexin 43 significantly improves multiple sclerosis symptoms in an experimental mouse model.

Afamitresgene autoleucel (afami-cel) is a novel cell therapy for the treatment of patients with synovial sarcoma.

The experimental drug successfully reduced levels of SIV, the nonhuman primate equivalent of HIV, in the brain.